Interestingly, their lifespans would probably be affected very little.
> GzmK does not affect steady-state immune aging or aged immune responses after challenge
Virtually all old mice die of cancer, especially in the lab. If GzmK doesn't mitigate immune system aging, GzmK-null mice are still going to die of cancer, for little or no change in lifespan. (But presumably an improved healthspan due to reduced soft tissue and bone aging.)
Humans have the same protein. Knock out studies in mice have historically been very informative about human biology (with some exceptions). That’s very different from drug studies, where the molecules not only have to have the same effect in the model species, but also all off target effects have to be similar. That’s a higher barrier to clear and why mice studies of pharmaceutical interventions should (and do) face higher scrutiny.
interesting, i exactly read the opposite position from biologists that the mice experiments are now very useful when it comes to applicability to humans. I guess we have every possible oppinion.
Granzyme K is the protein.
> GzmK does not affect steady-state immune aging or aged immune responses after challenge
Virtually all old mice die of cancer, especially in the lab. If GzmK doesn't mitigate immune system aging, GzmK-null mice are still going to die of cancer, for little or no change in lifespan. (But presumably an improved healthspan due to reduced soft tissue and bone aging.)